In July 2026, CITEST Diagnostics Inc. launched the Multiplex Respiratory Antigen Rapid Test, a professional?use in?vitro diagnostic product built for quick, qualitative pathogen screening from human nasopharyngeal swab samples. Engineered with multiplex lateral?flow immunoassay technology, this detection cassette identifies common respiratory pathogens and supplies auxiliary diagnostic evidence for infectious respiratory diseases, with readable outcomes ready within 15 minutes with no complicated lab?based equipment.
Designed for practical professional diagnosis, the Multiplex Respiratory Antigen Rapid Test possesses prominent functional advantages. It adopts a dual?sample?well layout that can test for up to 10 analytes in one cassette. Customizable analyte combinations are available, covering Flu B, Flu A, HPIV1/3, HPIV2, HMPV, BP, HBoV, Adeno, MP, RhV, RSV, COVID-19 and Strep A to satisfy varied screening demands. No testing apparatus is needed for straightforward operation, and fast?read results are obtainable in 15 minutes for time?saving and handy detection.
Constructed for dependable respiratory pathogen screening, this lateral?flow immunoassay test requires nasopharyngeal swab specimens and only basic operating skills. Its catalog number is RTRTCD(2-10)CI, each kit contains 20-test cassettes (20T). This product is restricted to professional in-vitro diagnostic application. Its detectable pathogens contain Adenovirus, human Parainfluenza virus, RSV, SARS-CoV-2, Mycoplasma pneumoniae, Rhinovirus, Influenza A/B, HMPV, Bordetella pertussis, Bocavirus and Group?A Streptococcus, covering major bacterial and viral triggers for upper and lower respiratory-tract infections.
The Multiplex Respiratory Antigen Rapid Test meets market requirements for comprehensive multi-pathogen respiratory screening. By integrating maximum-analyte detection, configurable panels and instrument?free simple operation, the new-release cassette strengthens CITEST's standing as a reputable supplier of rapid diagnostic supplies, focusing on efficiency and comprehensive coverage for clinical respiratory infection screening.
